WEST ST. PAUL, Minn. -- Tapemark has executed an agreement to acquire the iontoPatch® business from Travanti Pharma, Inc., a wholly owned subsidiary of Teikoku Pharma USA, Inc. The closing is scheduled to occur on August 31, 2011. After the closing, the iontoPatch® product line along with a suite of iontophoretic technology for use in medical devices and cosmetics will be marketed under the Travanti Medical name. Andy Rensink, President of Tapemark, explains, “Tapemark is excited to add the iontoPatch® technology to our existing delivery platforms SNAP® and SoluStrip® both of which support custom manufacturing solutions for a broad range of pharmaceutical, medical device and consumer products customers around the globe”.
The iontoPatch® product line is currently utilized extensively in the physical therapy market. Robert Arnold, General Manager of the newly formed Travanti Medical, states, “Combining product design, manufacturing and regulatory strategy in one entity allows us to more proactively and efficiently address performance enhancements strongly desired by our customers”.
Tapemark is a privately-held contract manufacturer with multiple facilities in West St. Paul, Minnesota, serving the medical, pharmaceutical, and consumer products markets. Supported single-use drug delivery formats include active and passive transdermal patches, topical patches and pads, soluble film, hydrogel, and Tapemark’s patented Snap!® packaging.
Tapemark provides medical devices such as test strips, dressings, sensors, and closure and attachment devices, and multi-layer, die-cut components used in a wide range of devices and applications. Tapemark is cGMP-compliant, ISO 9001 and 13485 certified, and FDA registered as a Drug, Device, and Food contract manufacturer. In addition, Tapemark is DEA registered as a Schedule III – V Manufacturer of Controlled Substances. Supporting its expanding global reach, Tapemark is EU-compliant and certified in Japan. Learn more about Tapemark at www.tapemark.com.